In Kessler et al. (1), the small molecule BI-2852 is shown to bind-at nanomolar affinity-to KRAS between switch I and II, inhibiting interactions with effectors. Here, we identify an alternative explanation for the inhibitory activity. While investigating the BI-2852 KRAS complex (Protein Data Bank [PDB] code 6GJ8), we noticed, by revealing the molecules in the neighboring unit cell, BI-2852 induces a KRAS dimer with rotational symmetry. This dimer complex consists of four molecules (two of BI-2852 and two of KRAS; Fig. 1A ).
To show BI-2852 induces dimers of KRAS, we performed the following: analysis of the crystal structures to characterize the dimer; performance of size exclusion column chromatography (SEC) experiments using protein with and without BI-2852, followed by analysis using native mass spectrometry; and measurement of binding affinity using isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).
Through structural analysis of PDB code 6GJ8, we identify critical interactions that stabilize the dimer (Fig. 1) . Focusing on the pocket formed about Lig1 (one of two copies of BI-2852), the pocket is formed by two KRAS molecules-with one KRAS forming a larger pocket (Basin) and a second KRAS molecule forming a smaller pocket (Lid) ( Fig. 1 A-D). There are two saltbridge interactions about Lig1: Lys5 of Ras1 interacts with Glu3 of Ras2, Asp54 of Ras1 interacts with the amine of Lig1, and the amine of Lig1 also interacts with Glu3 of Ras2 ( Fig. 1C In the SEC experiment, we observe the formation of a KRAS dimer in solution when BI-2852 is present and a monomer when ligand is absent (Fig. 1E This increased affinity over that of the SPR data is likely due to the avidity of the two compound binding sites and stabilization of the dimer. We surmise the ligand binds to both the Basin (switch I/II pocket) and the Lid (Fig. 1D) . These experimental observations are consistent with a dimer of KRAS stabilized by two molecules of BI-2852.
The biological effects of this compound, at least in part, are due to the formation of the KRAS dimer, resulting in enhanced binding affinity (22 μM to 720 nM). Moreover, the dimer occludes the binding footprint of the RAF1 RBD (Figshare [https://doi.org/ 10.6084/m9.figshare.11425995, Fig. S2; ref. 2] ). To our knowledge, such a structure of KRAS as a dimer has never been observed; albeit, this likely nonfunctional dimer is distinct from a biologically relevant KRAS multimer. The formation of a nonfunctional KRAS dimer seen in structures reported by Kessler et al. reveals a strategy of directly targeting KRAS. was funded in whole or in part with federal funds from National Cancer Institute-NIH Contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. 
